Ligand id: 7574

Name: dupilumab

No information available.
Summary of Clinical Use
Dupilumab was originally evaluated as a treatment for atopic allergic conditions, including asthma [3], atopic dermatitis (AD) and nasal polyposis [1]. A list of trials registered at ClinicalTrials.gov is available here.
The first full regulatory approval for dupilumab was granted by the FDA in March 2017 and this was for the treatment of moderate-to-severe eczema (atopic dermatitis). The EMA granted this same approval in August 2017. In October 2018, FDA approval was expanded to encompass the treatment of patients with eosinophilic type or oral corticosteroid-dependent moderate-to-severe asthma. June 2019 saw FDA approval expanded to include treatment of patients with uncontrolled chronic rhinosinusitis with nasal polyposis.
Mechanism Of Action and Pharmacodynamic Effects
Dupilumab is an IL-4 receptor α subunit (IL4Rα) inhibitor. IL4Rα is a component of the receptors which bind both interleukin (IL)-4 and IL-13. Interleukins 4 and 13 are released in response to Th2 cell activation in inflammatory reactions. By inhibiting both of these signalling pathways dupilumab effects a reduction of airway inflammation, as originally confirmed by results from clinical trials in patients with moderate-to-severe asthma [3].